The MoU sets down the guidelines for the establishment of an integrative medicine unit, joint research and academic activities in various fields of interest in Ayurveda and modern medicine
Ind-Ra maintains a neutral outlook for healthcare in FY23
Primarily set up to address the Covid-19 emergency, the WHO technology transfer hub has the potential to expand manufacturing capacity for other products as well, including treatments, and target other priorities such as malaria, HIV and cancer
Highlights the need for rebuilding, restructuring, and re-imagining resilient healthcare systems in India
Milltrust Ventures will also assist Oncoshot with its expansion in Australia and India, where the latter has already established partnerships amongst apex cancer institutes
The Gujarat Biotechnology policy released last month has made radical changes to position the state as a biotechnology hub. It already has a thriving ecosystem of pharma companies and varied suppliers
The company plans to establish a state-of-the-art greenfield pharma facility with a total of 4-6 manufacturing units in different therapeutics categories to cater to domestic and export markets
Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities
Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
Subscribe To Our Newsletter & Stay Updated
